Troy Wichterman Sells 25,687 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 25,687 shares of the stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total value of $582,067.42. Following the completion of the transaction, the chief financial officer now directly owns 189,242 shares in the company, valued at approximately $4,288,223.72. This represents a 11.95 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, March 11th, Troy Wichterman sold 4,151 shares of BioLife Solutions stock. The shares were sold at an average price of $25.00, for a total transaction of $103,775.00.
• On Monday, March 3rd, Troy Wichterman sold 660 shares of BioLife Solutions stock. The stock was sold at an average price of $25.46, for a total transaction of $16,803.60.
• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total transaction of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74.

BioLife Solutions Trading Down 7.0 %

BioLife Solutions stock opened at $20.88 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The firm’s 50 day moving average price is $25.87 and its 200-day moving average price is $25.48. BioLife Solutions, Inc. has a 1 year low of $14.84 and a 1 year high of $29.55. The stock has a market cap of $981.36 million, a P/E ratio of -19.70 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.32. The business had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the previous year, the company earned ($0.21) EPS. On average, equities analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BLFS has been the topic of several analyst reports. KeyCorp lifted their target price on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Benchmark reiterated a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. Northland Securities raised their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. StockNews.com lowered shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research report on Monday, March 31st. Finally, HC Wainwright raised their price objective on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.17.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors have recently added to or reduced their stakes in BLFS. Raymond James Financial Inc. purchased a new stake in shares of BioLife Solutions during the 4th quarter worth approximately $20,664,000. Massachusetts Financial Services Co. MA purchased a new stake in BioLife Solutions during the fourth quarter valued at $19,805,000. Point72 Asset Management L.P. bought a new position in BioLife Solutions during the fourth quarter valued at $11,113,000. Millennium Management LLC lifted its position in BioLife Solutions by 49.1% during the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock valued at $29,733,000 after purchasing an additional 377,111 shares during the last quarter. Finally, Rockefeller Capital Management L.P. increased its holdings in shares of BioLife Solutions by 40.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 821,764 shares of the medical equipment provider’s stock worth $21,333,000 after buying an additional 236,267 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.